Radico Remedies: Pharma Franchise, Pharma PCD, Pharmaceutical Contract Manufacturing Company Baddi India, manufacturing pharmaceutical companies.#Manufacturing #pharmaceutical #companies

Posted On Apr 23 2018 by

Pharmaceutical PCD Franchise, 3rd Party and Contract Manufacturing With World Class Manufacturing Facilities in Baddi India, Pharma manufacturer, marketing and PCD Franchise company Radico Remedies, is a single-point source for all your Pharma PCD, Pharma Franchise, 3rd party manufacturing contract manufacturing requirements in ophthalmology, dermatology, neuropsychiatry, veterinary generics. We are a GMP, GLP and ISO 9001:2008 Certified company. We are WHO GMP compliant pharma manufacturer in Baddi and have 30 years’ experience in manufacturing of pharmaceutical preparations in all gallanical forms. We offer Tablet, Capsules, Dry Syrups (Both beta and non-beta) Oral Liquids, Dry Injections, Liquid injections, External Preparations, Ointments, …


Determination of sodium hyaluronate in pharmaceutical formulations by HPLC–UV, pharmaceutical formulations.#Pharmaceutical #formulations

Posted On Apr 23 2018 by

pharmaceutical formulations Journal of Pharmaceutical Analysis Abstract A liquid chromatography (HPLC) method with UV detection was developed for determination of sodium hyaluronate in pharmaceutical formulation. Sodium hyaluronate is a polymer of disaccharides, composed of d -glucuronic acid and d -N-acetylglucosamine, linked via alternating β-1, 4 and β-1, 3 glycosidic bonds. Being a polymer compound it lacks a UV absorbing chromophore. In the absence of a UV absorbing chromophore and highly polar nature of compound, the analysis becomes a major challenge. To overcome these problems a novel method for the determination of sodium hyaluronate was developed and validated based on size …


Pharmaceutical Particle Size, Shape, Surface Area and Stability, pharmaceutical product.#Pharmaceutical #product

Posted On Apr 23 2018 by

pharmaceutical product in the Pharmaceutical Industry The particle size distribution of active ingredients and excipients is an important physical characteristic of the materials used to create pharmaceutical products. The size, distribution and shape of the particles can affect bulk properties, product performance, processability, stability and appearance of the end product. The link between particle size and product performance is well documented with regards to dissolution, absorption rates and content uniformity. Reducing particle size can aid the formulation of NCE’s with poor water solubility. Proper matching of active ingredient and excipient particle size is important for several process steps. Particle size …


Oral Solid Dosage Pharmaceutical Formulation Market – Global Industry Analysis, Size and Forecast, 2017 to 2027, pharmaceutical dosage forms.#Pharmaceutical #dosage #forms

Posted On Apr 23 2018 by

Oral Solid Dosage Pharmaceutical Formulation Market Segmentation By Dosage Form – Tablets, Capsules, Powders, Others; By Drug Release Mechanism – Immediate Release, Extended Release (Sustained Release, Controlled Release), Others; By Distribution Channel – Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy Oral Solid Dosage Pharmaceutical Formulation Market: Emerging Markets of Latin America, APEJ and MEA to Collectively Hold over 45% Market Value Share: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027 REP-GB-2782 2017-07-18 195 Pages Format: Category:Healthcare, Pharmaceuticals and Medical devices Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from …


Key Considerations in Excipients Selection for Solid Dosage Forms, Pharmaceutical Technology, pharmaceutical dosage forms.#Pharmaceutical #dosage #forms

Posted On Apr 23 2018 by

pharmaceutical dosage forms The majority of pharmaceutical drugs are still produced as solid dosage forms because of the acceptability and convenience of the oral route as well as the good patient compliance it offers in general. As solid dosage forms do not require sterile manufacturing conditions, the overall production costs are less expensive. Moreover, the pharmaceutical industry has years of experience developing solid dosage forms with well-defined and known processes, equipment, and technologies. To gauge emerging trends in solid dosage manufacturing, Pharmaceutical Technology spoke with Randy Wald, senior research fellow at Bend Research, part of Capsugel Dosage Form Solutions about …


Leading Global Pharmaceutical Company in India, Cipla Inc, ophthalmology pharmaceutical companies.#Ophthalmology #pharmaceutical #companies

Posted On Apr 23 2018 by

ophthalmology pharmaceutical companies Cipla is one of the top pharmaceutical companies in India, whose goal is to ensure that no patient shall be denied access to high quality affordable medicine and support. Our mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Online Pharmacy Warning: Cipla does not sell its products online and no guidelines for online sales are applicable.


Cipher Pharmaceuticals Announces Beteflam Patch Accepted For Review By Health Canada, cipher pharmaceuticals.#Cipher #pharmaceuticals

Posted On Apr 23 2018 by

Cipher Pharmaceuticals Announces Beteflam Patch Accepted For Review By Health Canada MISSISSAUGA, ON , Feb. 12, 2015 /PRNewswire/ – Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced that the Beteflam Patch (previously called the Betesil Patch) has been accepted for review by Health Canada. The Beteflam Patch is a novel, patent-protected, self-adhesive medicated plaster containing 0.1% betamethasone valerate, for the treatment of inflammatory skin conditions such as chronic plaque psoriasis (“CPP”). Topical corticosteroids remain the primary treatment for steroid-responsive inflammatory skin diseases, including mild to moderate CPP. Occlusion with plastic film dressings is a widely accepted …


About us, GSK, pharmaceutical companies in rtp.#Pharmaceutical #companies #in #rtp

Posted On Apr 23 2018 by

About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. About us What we do Our purpose and strategy Governance Comic Relief partnership Save the Children partnership We research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Products We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare Products Our consumer healthcare business has a portfolio of some of the world’s most trusted and best selling products in Pain Relief, Oral health, Respiratory, Nutrition and …


Non-sterile Process Validation in Pharmaceuticals: Pharmaceutical Guidelines, pharmaceutical process validation.#Pharmaceutical #process #validation

Posted On Apr 23 2018 by

Non-sterile Process Validation in Pharmaceuticals 1.2 The principles of planning, organizing and performing process validation are similar to those for qualification. It should be done in accordance with process validation protocols; data should be collected and reviewed against predetermined acceptance criteria, and reflected in process validation reports. 2.2 Normally process validation should cover at least the critical steps and parameters (e.g. those that may have an impact on the quality of the product) in the process of manufacturing a pharmaceutical product. 3.2 Process validation should normally begin only once qualification of support systems and equipment is completed. In some cases …


Addex Therapeutics: about addex, addex pharmaceuticals.#Addex #pharmaceuticals

Posted On Apr 23 2018 by

addex pharmaceuticals allosteric modulators for human health Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). In parallel, dipraglurant’s therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive …